Zyramod 25 Tablet contains 25 mg of Iguratimod, a disease-modifying antirheumatic drug (DMARD) primarily indicated for the treatment of rheumatoid arthritis. Iguratimod exerts its therapeutic effects by inhibiting the production of pro-inflammatory cytokines and suppressing the activation of nuclear factor-kappa B (NF-κB), thereby reducing inflammation and joint damage. It also modulates immune responses by decreasing immunoglobulin synthesis and inhibiting the proliferation of synovial fibroblasts. Zyramod 25 is prescribed to patients with active rheumatoid arthritis who have shown inadequate response to conventional therapies, aiming to improve clinical symptoms, physical function, and quality of life. The recommended dosage should be adhered to as per physician guidance, with regular monitoring for potential adverse effects such as gastrointestinal disturbances, liver enzyme elevations, and hematological abnormalities. Caution is advised in patients with hepatic or renal impairment, and concurrent use with other immunosuppressive agents requires careful supervision. Zyramod 25 should be used under strict medical supervision, with periodic assessment of therapeutic efficacy and safety parameters to optimize treatment outcomes and minimize risks. It is contraindicated in patients with known hypersensitivity to Iguratimod or any excipients in the formulation.